The brief examines the potential impact of Aduhelm, a newly approved drug for Alzheimer’s disease, on state and federal Medicaid costs and looks at potential policy actions that could limit Medicaid’s potential costs.
How Might the FDA’s Approval of a New Alzheimer’s Drug Impact Medicaid?
